



# Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares

Pursuant to the Market Abuse Regulation article 19, Gubra A/S, CVR no. 30514041 (the "Company") hereby notifies receipt of information of the following transactions made by persons discharging managerial responsibilities in the Company and persons closely associated with them in the Company's shares and other financial instruments linked thereto.

<b>1.</b>	<b>Details of the person discharging managerial responsibilities/person closely associated</b>		
a)	Name	Kristian Borbos	
<b>2.</b>	<b>Reason for the notification</b>		
a)	Position/status	CFO in Gubra	
b)	Initial notification/ Amendment	Initial notification	
<b>3.</b>	<b>Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor</b>		
a)	Name	Gubra A/S	
b)	LEI	254900T17RRFZONO6W53	
<b>4.1</b>	<b>Details of the transaction(s):</b>		
a)	Description of the financial instrument, type of instrument	Shares	
	Identification code	ISIN DK0062266474	
b)	Nature of the transaction	Sale of shares to cover taxes	
c)	Price(s) and volume(s)	Price(s)	Volume(s)



		DKK 530	2,943
		DKK 532	24
		DKK 534	33
d)	Aggregated information — Aggregated volume — Price	Average price per share: DKK 530.06 Total number of shares: 3,000 Total price: DKK 1,590,180	
e)	Date of the transaction	10 July 2024	
f)	Place of the transaction	NASDAQ Copenhagen A/S	

### Contacts at Gubra

Media: Sofia Pitt Boserup, [sbo@gubra.dk](mailto:sbo@gubra.dk), +45 4188 9586

Investors: Kristian Borbos, [kbo@gubra.dk](mailto:kbo@gubra.dk), +45 3080 8035

### About Gubra

Gubra, founded in 2008 in Denmark, listed on NASDAQ Copenhagen, is specialized in pre-clinical contract research services and peptide-based drug discovery within metabolic and fibrotic diseases. Gubra's activities are focused on the early stages of drug development and are organised in two business areas – CRO Services and Discovery & Partnerships (D&P). The two business areas are highly synergistic and create a unique entity capable of generating a steady cash flow from the CRO business while at the same time enjoying biotechnology upside in the form of potential development milestone payments and potential royalties from the D&P business. In 2023, Gubra had approx. 220 employees and revenue of DKK 205 million. See [www.gubra.dk](http://www.gubra.dk) for more information.

*This information is information that Gubra is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-07-10 23:38 CEST.*

### Attachments

[Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares](#)